医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ReproCELL Announced: Sales Commencement of “ReproNeuro MQ Medium”, a Cell Culture Kit Which Enables the Creation of High-Functioning Nerve Cells Derived from Human iPS Cells

2015年07月22日 PM10:00
このエントリーをはてなブックマークに追加


 

YOKOHAMA, Japan

This is a notice that we will on August 3rd commence sales of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells.

The “ReproNeuro” series which we have sold so far enables the creation of nerve cells from human iPS cells, and has been widely used by pharmaceutical companies during the drug development process for the evaluation of nerve cell toxicity. It has been highly rated for its ability to reduce the number of experiments previously required to be performed on animal subjects. At ReproCELL we have continued our research and development in order to bring these nerve cells closer to the ideal of being like those within a living human body.

With this new “ReproNeuro MQ Medium”, we have developed a specialist culture fluid for making nerve cells, and succeeded in increasing the electrical activity of nerve cells created from iPS cells. We expect this to distinguish our company`s superior nerve cell development, to lead to both an improvement in the reliability of and expansion in the utility of toxicity evaluations in the drug development process, and to contribute to a major reduction in the cost of the drug development process.

For more information, visit: https://www.reprocell.com/en/

View source version on businesswire.com: http://www.businesswire.com/news/home/20150722005541/en/

CONTACT

ReproCELL, Inc. (JASDAQ:4978)
Chikafumi Yokoyama, +81-45-475-3887
PhD
info_en@reprocell.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • PerkinElmer Acquires Shanghai Spectrum Instruments Co., Ltd.
  • 珀金埃尔默收购上海光谱仪器有限公司
  • 据国际睡眠专家估计,全球有近10亿人罹患睡眠呼吸暂停
  • 世界中で10億人近くが睡眠時無呼吸症を患っていると世界の睡眠専門家らが推定
  • Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer’s Disease